Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and ixazomib

erlotinib hydrochloride has been researched along with ixazomib in 1 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(ixazomib)		Trials
(ixazomib)		Recent Studies (post-2010) (ixazomib)
4,3537863,03330078289

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)ixazomib (IC50)
Proteasome subunit beta type-11Homo sapiens (human)0.015
Proteasome subunit alpha type-7Homo sapiens (human)0.015
Proteasome subunit beta type-1Homo sapiens (human)0.0163
Proteasome subunit alpha type-1Homo sapiens (human)0.015
Proteasome subunit alpha type-2Homo sapiens (human)0.015
Proteasome subunit alpha type-3Homo sapiens (human)0.015
Proteasome subunit alpha type-4Homo sapiens (human)0.015
Proteasome subunit beta type-8Homo sapiens (human)0.015
Proteasome subunit beta type-9Homo sapiens (human)0.015
Proteasome subunit alpha type-5Homo sapiens (human)0.015
Proteasome subunit beta type-4Homo sapiens (human)0.015
Proteasome subunit beta type-6Homo sapiens (human)0.015
Proteasome subunit beta type-5Homo sapiens (human)0.0065
Proteasome subunit beta type-10Homo sapiens (human)0.015
Proteasome subunit beta type-3Homo sapiens (human)0.015
Proteasome subunit beta type-2Homo sapiens (human)1.1817
Proteasome subunit alpha type-6Homo sapiens (human)0.015
ATP-dependent Clp protease proteolytic subunitStaphylococcus aureus subsp. aureus NCTC 83255.3
NACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)0.1995
Proteasome subunit alpha-type 8Homo sapiens (human)0.015
Proteasome subunit beta type-7Homo sapiens (human)0.015

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Adashek, JJ; Brown, EJ; Fu, S; Hong, DS; Karp, DD; Kato, S; Nguyen, L; Piha-Paul, SA; Subbiah, V; Sun, M; Yap, TA1

Trials

1 trial(s) available for erlotinib hydrochloride and ixazomib

ArticleYear
A phase i study of ixazomib and erlotinib in patients with advanced solid tumors.
    Investigational new drugs, 2022, Volume: 40, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Glycine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; NF-kappa B

2022